Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H2, 2016

GlobalData
446 Pages - GLDATA58524
$2,500.00

Summary

GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H2, 2016" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Eli Lilly and Company
AstraZeneca Plc
F. Hoffmann-La Roche Ltd.
Sanofi
Bayer AG
Merck & Co., Inc.
GlaxoSmithKline Plc
Novartis AG
Celgene Corporation
Agios Pharmaceuticals, Inc.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Bile Duct Cancer (Cholangiocarcinoma) 31
Oct 17, 2016: Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week 31
Oct 08, 2016: Leap Therapeutics Presents Positive Top-line Results of DKN-01 Combination Therapy for Cholangiocarcinoma at the European Society for Medical Oncology 2016 Congress 31
Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 32
Clinical Trial Profile Snapshots 33
Appendix 443
Abbreviations 443
Definitions 443
Research Methodology 444
Secondary Research 444
About GlobalData 445
Contact Us 445
Disclaimer 445
Source 446

List of Tables
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 444

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports